First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and PD-L1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial -
3 days ago
- #tislelizumab
- #PD-L1
- #ES-SCLC
- First-line tislelizumab plus chemotherapy showed significant improvements in overall survival (OS) compared to placebo plus chemotherapy in extensive-stage SCLC (ES-SCLC).
- The RATIONALE-312 trial revealed a median OS of 15.5 months for tislelizumab versus 13.5 months for placebo (HR = 0.78).
- OS benefits were consistent across PD-L1 expression subgroups.
- Common treatment-related adverse events included alopecia, anemia, and neutropenia, with similar rates in both groups.
- Long-term follow-up confirmed sustained OS benefits and tolerable safety for tislelizumab plus chemotherapy.